D M Ashcroft

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. pmc Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Arthritis Care Res (Hoboken) 62:345-53. 2010
  2. pmc Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
    Moetaza M Soliman
    University of Manchester, UK
    Arthritis Care Res (Hoboken) 64:1108-15. 2012
  3. pmc Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Rheumatology (Oxford) 49:697-705. 2010
  4. pmc Medication safety in community pharmacy: a qualitative study of the sociotechnical context
    Denham L Phipps
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    BMC Health Serv Res 9:158. 2009
  5. pmc Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK
    Arthritis Res Ther 11:R52. 2009
  6. pmc Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials
    Darren M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL
    BMJ 330:516. 2005
  7. pmc Safety culture assessment in community pharmacy: development, face validity, and feasibility of the Manchester Patient Safety Assessment Framework
    D M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Qual Saf Health Care 14:417-21. 2005
  8. pmc Likelihood of reporting adverse events in community pharmacy: an experimental study
    D M Ashcroft
    Centre for Innovation in Practice, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK
    Qual Saf Health Care 15:48-52. 2006
  9. ncbi request reprint Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists
    D M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Oxford Road, Manchester, UK
    Br J Dermatol 155:1236-41. 2006
  10. ncbi request reprint Retrospective analysis of medication incidents reported using an on-line reporting system
    Darren M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, M13 9PL, Manchester, UK
    Pharm World Sci 28:359-65. 2006

Detail Information

Publications29

  1. pmc Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Arthritis Care Res (Hoboken) 62:345-53. 2010
    ..To evaluate the impact of anti-tumor necrosis factor (anti-TNF) therapies on quality of life (QOL) and functional status in psoriatic arthritis (PsA) patients and study potential predictors for QOL improvements...
  2. pmc Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
    Moetaza M Soliman
    University of Manchester, UK
    Arthritis Care Res (Hoboken) 64:1108-15. 2012
    ....
  3. pmc Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Rheumatology (Oxford) 49:697-705. 2010
    ..To evaluate the risk-benefit profile of anti-TNF therapies in PsA and to study the predictors of treatment response and disease remission [disease activity score (DAS)-28 < 2.6]...
  4. pmc Medication safety in community pharmacy: a qualitative study of the sociotechnical context
    Denham L Phipps
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    BMC Health Serv Res 9:158. 2009
    ..The aim of this study was to identify sociotechnical factors that community pharmacy staff encounter in practice, and suggest how these factors might impact on medication safety...
  5. pmc Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK
    Arthritis Res Ther 11:R52. 2009
    ....
  6. pmc Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials
    Darren M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL
    BMJ 330:516. 2005
    ..To determine the efficacy and tolerability of topical pimecrolimus and tacrolimus compared with other treatments for atopic dermatitis...
  7. pmc Safety culture assessment in community pharmacy: development, face validity, and feasibility of the Manchester Patient Safety Assessment Framework
    D M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Qual Saf Health Care 14:417-21. 2005
    ..To develop a framework that could be used by community pharmacies to self-assess their current level of safety culture maturity, which has high face validity and is both acceptable and feasible for use in this setting...
  8. pmc Likelihood of reporting adverse events in community pharmacy: an experimental study
    D M Ashcroft
    Centre for Innovation in Practice, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK
    Qual Saf Health Care 15:48-52. 2006
    ..Little is known about levels of engagement with the NRLS...
  9. ncbi request reprint Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists
    D M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Oxford Road, Manchester, UK
    Br J Dermatol 155:1236-41. 2006
    ..The choice of drug treatment for an individual patient is a complex matter. In the case of psoriasis there is a range of treatments available, with varying degrees of efficacy and risk of adverse events...
  10. ncbi request reprint Retrospective analysis of medication incidents reported using an on-line reporting system
    Darren M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, M13 9PL, Manchester, UK
    Pharm World Sci 28:359-65. 2006
    ..To examine the types of prescribing, administration and dispensing incidents reported to an on-line incident-reporting scheme and determine the types of healthcare professionals responsible for reporting such incidents...
  11. doi request reprint Development of the pharmacy safety climate questionnaire: a principal components analysis
    D M Ashcroft
    Centre for Innovation in Practice, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Qual Saf Health Care 18:28-31. 2009
    ..To develop, and examine the component structure and internal consistency, of a questionnaire designed to assess safety climate in the community pharmacy setting...
  12. doi request reprint Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre
    R B Warren
    Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester M6 8HD, UK
    Br J Dermatol 160:162-9. 2009
    ..However, to date, there are few reports of the practical use of these therapies outside of the trial setting and, to our knowledge, none from a U.K. cohort of patients with psoriasis...
  13. ncbi request reprint Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    J Rheumatol 35:883-90. 2008
    ..To evaluate the efficacy and safety of tumor necrosis factor-alpha (TNF-alpha) inhibitors in the management of psoriatic arthritis (PsA)...
  14. ncbi request reprint Determinants of the uptake of medicines use reviews (MURs) by community pharmacies in England: a multi-method study
    Fay Bradley
    Centre for Innovation in Practice, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK
    Health Policy 88:258-68. 2008
    ..To explore and identify the key determinants influencing the uptake of medicines use reviews (MURs), a new community pharmacy service in England...
  15. doi request reprint Prevalence, incidence and nature of prescribing errors in hospital inpatients: a systematic review
    Penny J Lewis
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Drug Saf 32:379-89. 2009
    ..Future research should address the wide disparity of data-collection methods and definitions that bedevils comparison of error rates or meta-analysis of different studies...
  16. doi request reprint The causes of and factors associated with prescribing errors in hospital inpatients: a systematic review
    Mary P Tully
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Drug Saf 32:819-36. 2009
    ..Further rigorous study, seeking potential ways of reducing error, needs to be conducted. Multifactorial interventions across many parts of the system are likely to be required...
  17. ncbi request reprint Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study
    Li Chia Chen
    School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, 1st Floor, Stopford Building, Oxford Road, Manchester, M13 9PT, UK
    Pharm World Sci 29:661-70. 2007
    ....
  18. doi request reprint Changing patient consultation patterns in primary care: an investigation of uptake of the Minor Ailments Service in Scotland
    Andrew Wagner
    Centre for Innovation in Practice, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK
    Health Policy 99:44-51. 2011
    ..The MAS was introduced in 2006, intending to improve health care access by re-directing patients from primary care to community pharmacies...
  19. doi request reprint The challenge of integrating community pharmacists into the primary health care team: a case study of local pharmaceutical services (LPS) pilots and interprofessional collaboration
    Fay Bradley
    Centre for Innovation in Practice, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    J Interprof Care 22:387-98. 2008
    ..The findings suggest that establishing interprofessional collaboration between GPs and pharmacists is a piecemeal process, with a reliance on goodwill and trust-based relationships...
  20. pmc Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis
    J Thornton
    Arthritis Research Campaign Epidemiology Unit, Division of Epidemiology and Health Sciences, University of Manchester, Manchester, UK
    Rheumatology (Oxford) 47:985-90. 2008
    ..The aim of this study was to obtain patient-based costs for treating children with JIA in the UK, in the first year from diagnosis and from the secondary health care payer perspective...
  21. ncbi request reprint Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies
    Chuenjid Kongkaew
    School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, UK
    Ann Pharmacother 42:1017-25. 2008
    ..To determine the prevalence of hospital admissions associated with ADRs and examine differences in prevalence rates between population groups and methods of ADR detection...
  22. ncbi request reprint Prospective study of the incidence, nature and causes of dispensing errors in community pharmacies
    Darren M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Pharmacoepidemiol Drug Saf 14:327-32. 2005
    ..Despite this, there is little published evidence relating to dispensing errors and near misses occurring in this setting. This study sought to determine their incidence, nature and causes...
  23. ncbi request reprint Influence of prescription charges on repeat prescribing in primary care
    F Bradley
    Centre for Innovation in Practice, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    J Clin Pharm Ther 32:269-75. 2007
    ..Little is known about how the charge status of the patient may impact on the uptake and prescribing practices of this service...
  24. ncbi request reprint Optimal management of severe plaque form of psoriasis
    David A Fairhurst
    Dermatology Centre, Hope Hospital, The University of Manchester, Manchester, UK
    Am J Clin Dermatol 6:283-94. 2005
    ..Importantly, treatment should be tailored to each individual patient depending on concurrent medical problems (which might preclude certain agents), patient choice and acceptance of the risk of adverse effects...
  25. ncbi request reprint Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis
    Elizabeth M Seston
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PT, England
    Arch Dermatol 143:1175-9. 2007
    ..To examine the extent to which the attributes of a treatment affect patients' choice of treatment for psoriasis and the magnitude and nature of trade-offs between risks and benefits of treatment...
  26. ncbi request reprint Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials
    Darren M Ashcroft
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK
    Pharmacoepidemiol Drug Saf 13:73-82. 2004
    ..To evaluate the comparative efficacy and tolerability of naratriptan in the treatment of acute attacks of migraine...
  27. doi request reprint Therapeutic interventions for vitiligo
    Maxine E Whitton
    Cochrane Skin Group, Nottingham, United Kingdom
    J Am Acad Dermatol 59:713-7. 2008
    ..Current treatments for vitiligo, a common pigmentary disorder affecting around 1% of the world's population, are largely unsatisfactory...
  28. pmc Identifying criteria for the assessment of pharmacy students' communication skills with patients
    Adele Mackellar
    Pharmacy Department, South Manchester University Hospitals NHS Trust, UK
    Am J Pharm Educ 71:50. 2007
    ..To identify criteria by which patients can assess the communication skills of pharmacy students...
  29. ncbi request reprint Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study
    Darren M Ashcroft
    Department of Medicines Management, Keele University, Keele, Staffordshire ST5 5BG, UK
    Pharmacoepidemiol Drug Saf 11:285-9. 2002
    ..Newer, more expensive, 'atypical' antipsychotics have been developed in attempts to address these problems, although debate about the most appropriate role for these medications remains...